Skip to main content
. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7

Fig. 3. Overall survival by prior TKI status in patients with R/R AML treated with gilteritinib: CHRYSALIS and ADMIRAL trials combined (120 mg only).

Fig. 3

AML acute myeloid leukemia, CI confidence interval, OS overall survival, R/R relapsed or refractory, TKI tyrosine kinase inhibitor.